Case Details
- Citation: [2025] SGHC 28
- Court: General Division of the High Court of the Republic of Singapore
- Decision Date: 21 February 2025
- Coram: Kristy Tan JC
- Case Number: Originating Application No 963 of 2024
- Hearing Date(s): 6, 13 January 2025
- Claimants / Plaintiffs: India Glycols Ltd; IGL Chem International USA LLC; Dharmesh Mehta
- Respondent / Defendant: Texan Minerals and Chemicals LLC
- Counsel for Claimants: Siraj Omar SC, Larisa Cheng and Robbie Tan (Siraj Omar LLC)
- Counsel for Respondent: Colin Seow Fu Hong and Huang Qianwei (Colin Seow Chambers)
- Practice Areas: International arbitration; Setting aside of arbitral awards; Breach of natural justice; Excess of jurisdiction
Summary
The decision in India Glycols Ltd and others v Texan Minerals and Chemicals LLC [2025] SGHC 28 serves as a critical reminder of the jurisdictional boundaries that constrain arbitral tribunals, particularly in multi-party disputes involving distinct contractual instruments. The case concerned an application by India Glycols Ltd ("IGL"), its subsidiary IGL Chem International USA LLC ("ICI"), and their director Dharmesh Mehta (collectively, the "Respondents" in the arbitration) to partially set aside an arbitral award issued on 19 June 2024. The dispute originated from the supply of hand sanitizers that allegedly failed to meet US Food and Drug Administration (FDA) standards, specifically regarding current Good Manufacturing Practices (cGMP).
The claimants sought to set aside the Award on two primary grounds. Ground 1 alleged a breach of natural justice under s 24(b) of the International Arbitration Act 1994 and Art 34(2)(a)(ii) of the UNCITRAL Model Law. The claimants argued that the Tribunal had adopted a "chain of reasoning" regarding the causation of damages and the application of a "Break Even Presumption" under English law that had not been properly ventilated during the proceedings. Ground 2 alleged an excess of jurisdiction under Art 34(2)(a)(iii) of the Model Law, contending that the Tribunal improperly held ICI and Dharmesh Mehta liable for breaches of a contract—the Manufacturer Representation Agreement (MRA)—to which they were not parties.
Kristy Tan JC dismissed the natural justice challenge. The Court held that the Tribunal’s reasoning on the counterfactual scenario (i.e., what would have occurred had the manufacturing facilities been cGMP-compliant) was a matter of factual inference and legal application that fell within the scope of the issues submitted. The Court emphasized that a tribunal is not required to invite parties to submit on every intermediate step of its reasoning, provided the core issues are "in play." The application of the "Break Even Presumption" was viewed as a permissible application of the governing English law to the facts found.
However, the Court found merit in Ground 2. While all three claimants were parties to a subsequent Arbitration Agreement, only IGL was a party to the underlying MRA. The Tribunal had found all three claimants liable for damages arising from the breach of the MRA. The Court determined that the scope of the submission to arbitration did not include a claim that ICI or Dharmesh were parties to, or liable under, the MRA. By imposing liability on non-signatories to the substantive contract, the Tribunal exceeded its jurisdiction. Consequently, the Court set aside the portion of the Award holding ICI and Dharmesh liable for US$261,275.89 in damages, while maintaining the liability of IGL.
Timeline of Events
- 23 February 2021: Texan and IGL executed the Manufacturer Representation Agreement (MRA), appointing Texan as the exclusive distributor of hand sanitizers in North America.
- September 2020 – March 2021: Texan placed purchase orders with ICI for hand sanitizers manufactured by IGL in India.
- June 2021: Texan raised quality concerns regarding the hand sanitizer products received in retail containers.
- 3 May 2022: Texan alleged that the products were not manufactured in compliance with FDA cGMP and demanded reimbursement of US$1,050,000.
- 1 March 2023: Texan, IGL, ICI, and Dharmesh Mehta executed a standalone Arbitration Agreement to resolve their disputes via SIAC arbitration.
- 16 March 2023: Texan commenced arbitration proceedings against IGL, ICI, and Dharmesh.
- 7 September 2023: Texan filed its Statement of Claim in the arbitration.
- 13 October 2023: The Respondents (IGL, ICI, and Dharmesh) filed their Statement of Defence and Counterclaim.
- 14 February 2024: The Tribunal issued a list of 24 issues to be determined.
- 19 June 2024: The Tribunal issued the Final Award, finding a breach of the MRA and awarding damages.
- 13 November 2024: The Claimants filed HC/OA 963/2024 to set aside the Award in part.
- 6, 13 January 2025: Substantive hearing of the setting-aside application before Kristy Tan JC.
- 21 February 2025: The High Court delivered its judgment, partly allowing the application.
What Were the Facts of This Case?
The dispute involved four primary actors. India Glycols Ltd ("IGL") is an Indian manufacturer of chemicals. IGL Chem International USA LLC ("ICI") is its US-based subsidiary responsible for marketing and distribution. Dharmesh Mehta ("Dharmesh") is a director of ICI. The Respondent, Texan Minerals and Chemicals LLC ("Texan"), is a Texas-based wholesaler. The commercial relationship centered on the supply of hand sanitizers during the COVID-19 pandemic.
The parties' relationship was governed by the Manufacturer Representation Agreement (MRA) dated 23 February 2021, signed only by IGL and Texan. Clause 4.8 of the MRA was a pivotal provision, requiring IGL to "maintain a robust quality assurance program including GMP as required by USA FDA." Between late 2020 and early 2021, Texan ordered ten bulk containers of hand sanitizer. While the products were manufactured by IGL, the purchase orders were placed with ICI. The products were shipped directly from India to Texan's facilities in the United States.
The conflict escalated when the US Food and Drug Administration (FDA) placed IGL on an "Import Alert" list. Texan alleged that the hand sanitizers were not manufactured in compliance with current Good Manufacturing Practices (cGMP), rendering them unsellable in the US market. Texan refused to pay invoices totaling US$127,698.20 for certain retail containers and sought reimbursement for storage and disposal costs. On 3 May 2022, Texan formally alleged breaches of the MRA and the Sale of Goods Act 1979, claiming the products were not fit for purpose.
To resolve these issues, the parties entered into a separate Arbitration Agreement on 1 March 2023. This agreement was broader in scope than the MRA's original arbitration clause, as it included ICI and Dharmesh as parties. The arbitration was conducted under the Singapore International Arbitration Centre (SIAC) rules. Texan’s claims in the arbitration included breach of the MRA, breach of the Sale of Goods Act 1979, and various warranties. The Respondents (IGL, ICI, and Dharmesh) counterclaimed for the unpaid invoice amounts.
In the Award dated 19 June 2024, the Tribunal found that IGL had breached clause 4.8 of the MRA by failing to ensure its facilities were cGMP-compliant. Crucially, the Tribunal held that although Texan could not prove it would have definitely sold the products but for the breach (due to the FDA Import Alert), it was entitled to damages based on a "Break Even Presumption" under English law. This presumption assumes that a party entering a contract would at least have recovered its expenses. The Tribunal awarded Texan US$388,974.09 for storage and disposal costs. After setting off the US$127,698.20 owed to the Respondents for the products, the net damages award was US$261,275.89. The Tribunal held all three Respondents—IGL, ICI, and Dharmesh—jointly and severally liable for this sum.
What Were the Key Legal Issues?
The application for setting aside raised two distinct legal challenges to the Award:
- Ground 1: Breach of Natural Justice (Fair Hearing Rule). The Claimants argued that the Tribunal breached the principles of natural justice under s 24(b) of the International Arbitration Act 1994 and Art 34(2)(a)(ii) of the Model Law. The specific grievance was that the Tribunal decided the issue of causation and damages based on a "Break Even Presumption" and a specific counterfactual scenario (that Texan could have sold the products if they were cGMP-compliant) that were never pleaded by Texan or argued during the hearing.
- Ground 2: Excess of Jurisdiction. The Claimants contended that the Tribunal exceeded its jurisdiction under Art 34(2)(a)(iii) of the Model Law. The core of this issue was whether the Tribunal had the authority to find ICI and Dharmesh liable for a breach of the MRA. The Claimants argued that since ICI and Dharmesh were not parties to the MRA, and Texan had not pleaded that they were parties to the MRA, the Tribunal's decision to hold them liable fell outside the scope of the submission to arbitration.
These issues required the Court to balance the principle of minimal curial intervention in arbitration against the necessity of ensuring that tribunals remain within the bounds of the parties' consent and procedural fairness.
How Did the Court Analyse the Issues?
The Court’s analysis was divided into two major segments corresponding to the two grounds of the application.
Ground 1: Natural Justice and the "Break Even Presumption"
The Claimants’ primary complaint under Ground 1 was that the Tribunal adopted a "chain of reasoning" that was not ventilated. Specifically, they argued that the Tribunal's finding—that Texan would have been able to sell the products in the counterfactual scenario where IGL was cGMP-compliant—was a "new point." They further argued that the Tribunal's reliance on the "Break Even Presumption" under English law was a surprise.
Kristy Tan JC applied the established tests for natural justice, referencing BZW and another v BZV [2022] 1 SLR 1080 and CJA v CIZ [2022] 2 SLR 557. The Court noted that a "chain of reasoning" is not a breach of natural justice if it is "open to the Tribunal" based on the materials and arguments presented. The Court found that the issue of whether the products were sellable (the "fitness for purpose" and "merchantable quality" issues) was a central theme of the arbitration. At paragraph [33], the Court observed:
"the chain of reasoning that Texan would have been able to sell the products if there was cGMP-compliance (ie, in the counterfactual scenario) was open to the Tribunal and there was no breach of the fair hearing rule"
Regarding the "Break Even Presumption," the Court noted that the MRA was governed by English law. The Tribunal had taken "judicial notice" of the presumption that a claimant would have at least broken even on its expenses but for the breach. The Court held that this was not a new "issue" but rather a rule of law applied to the issue of damages, which was clearly before the Tribunal. The Court cited TMM Division Maritima SA de CV v Pacific Richfield Marine Pte Ltd [2013] 4 SLR 972, noting that a tribunal does not need to consult parties on every rule of law it intends to apply to the pleaded issues. Consequently, Ground 1 was dismissed.
Ground 2: Excess of Jurisdiction regarding ICI and Dharmesh
The analysis of Ground 2 was more technical, involving the "two-stage enquiry" for excess of jurisdiction as set out in ACM Equipment Co Ltd v Tornado Consumer Goods Ltd and another matter [2018] 4 SLR 271 and Bloomberry Resorts and Hotels Inc and another v Global Gaming Philippines LLC and another [2021] 2 SLR 1279. The two stages are: (1) identifying what matters were submitted to the tribunal; and (2) determining whether the tribunal decided a matter not submitted.
The Court scrutinized the 1 March 2023 Arbitration Agreement. While this agreement brought ICI and Dharmesh into the arbitration, it did not retrospectively make them parties to the MRA. The Court examined Texan's Statement of Claim and the List of Issues. It found that Texan had consistently pleaded that the MRA was a contract between "Claimant [Texan] and Respondents [IGL, ICI, and Dharmesh]," but the actual text of the MRA only named IGL. Crucially, the Tribunal had found that ICI and Dharmesh "made contractual promises under the MRA" and "breached the MRA."
The Court found that the Tribunal had conflated the parties to the arbitration with the parties to the MRA. Kristy Tan JC held that there was no basis in the pleadings or the evidence for the Tribunal to find that ICI and Dharmesh were parties to the MRA. At paragraph [91], the Court concluded:
"the Tribunal’s decisions that (a) ICI and Dharmesh made contractual promises under the MRA; (b) ICI and Dharmesh breached the MRA; and (c) ICI and Dharmesh were liable for damages for breach of the MRA, were decisions on matters falling outside the scope of the submission to arbitration."
The Court emphasized that the scope of submission is determined by the pleadings and the arbitration agreement. Since the MRA was clearly a bilateral contract between IGL and Texan, and no legal basis (such as agency or piercing the corporate veil) had been pleaded to hold ICI or Dharmesh liable for IGL's breach of the MRA, the Tribunal's award against them was an excess of jurisdiction.
What Was the Outcome?
The High Court ordered a partial setting aside of the Final Award. The Court upheld the Tribunal's findings against IGL, including the finding of breach of clause 4.8 of the MRA and the resulting liability for damages. However, the Court set aside the Award insofar as it imposed liability on ICI and Dharmesh Mehta.
The operative order of the Court, found at paragraph [100], stated:
"I therefore order that the part of the Award concerning the Tribunal’s decision that ICI and Dharmesh are liable to pay Texan damages for breach of the MRA, as well as the Tribunal’s order that ICI and Dharmesh pay such damages in the sum of US$261,275.89 to Texan, be set aside."
The practical effect of this decision was that Texan retained its judgment for US$261,275.89 against IGL (the primary manufacturer), but lost its recourse against the US subsidiary (ICI) and the individual director (Dharmesh). The set-off of US$127,698.20 (the unpaid invoices) remained applicable to the calculation of the final sum due from IGL.
Regarding costs, the Court did not make an immediate order. Instead, it directed the parties to file written submissions on costs within two weeks of the judgment (by 7 March 2025), limited to three pages, unless they could reach an agreement independently. This reflects the standard practice in the General Division for complex arbitration-related applications where the outcome is a partial success for the applicant.
Why Does This Case Matter?
This judgment is a significant contribution to Singapore's arbitration jurisprudence for several reasons. First, it clarifies the distinction between being a party to an arbitration agreement and being a party to the underlying substantive contract. In multi-party disputes, practitioners often use broad arbitration agreements to consolidate disputes. However, this case demonstrates that such consolidation does not automatically expand the substantive liability of all parties to every contract involved in the dispute. A tribunal must still find a legal basis to hold a party liable under a specific contract, and that basis must be within the scope of the parties' submission.
Second, the case reinforces the "minimal curial intervention" principle regarding natural justice. The Court’s refusal to set aside the Award based on the "Break Even Presumption" shows that Singapore courts will not entertain challenges that are essentially disguised appeals on the merits of the law or the facts. If a tribunal applies a legal principle (like an English law presumption) to a pleaded issue (like damages), it is generally not a breach of natural justice, even if the specific presumption was not debated in detail. This provides certainty to the finality of awards.
Third, the decision provides a clear application of the Bloomberry Resorts two-stage test for Art 34(2)(a)(iii). It highlights that the "scope of submission" is a matter of objective interpretation of the pleadings and the arbitration agreement. Practitioners must be meticulous in their pleadings to ensure that every head of liability against every party is clearly articulated and grounded in the relevant contracts. Failure to do so risks the award being set aside for excess of jurisdiction.
Finally, the case touches upon the "Break Even Presumption" in English law, which is of interest to practitioners dealing with damages in commercial contracts. The Court's acceptance of the Tribunal's "judicial notice" of this presumption suggests a pragmatic approach to how tribunals apply the governing law of the contract to fill gaps in the evidence of loss.
Practice Pointers
- Distinguish Arbitration Parties from Contract Parties: When drafting a multi-party arbitration agreement to resolve disputes arising from a bilateral contract, clearly define which parties are being sued for which breaches. Do not assume that joining a party to the arbitration makes them liable for the underlying contract.
- Plead Specific Legal Bases for Non-Signatory Liability: If seeking to hold a non-signatory (like a parent company or director) liable for a contract breach, specifically plead the legal basis (e.g., agency, alter ego, or collateral contract). The Court in this case noted the absence of such pleadings as a factor in finding an excess of jurisdiction.
- Anticipate Counterfactual Arguments: In damages claims, the "counterfactual scenario" is almost always "in play." Practitioners should proactively address what would have happened but for the breach, as tribunals are entitled to make inferences on this without further inviting submissions.
- Be Aware of Governing Law Presumptions: If a contract is governed by English law (or another foreign law), be aware of standard presumptions like the "Break Even Presumption." These can be applied by the tribunal as part of its legal analysis of a pleaded issue.
- Review the List of Issues Carefully: The List of Issues is a critical document for determining the scope of the submission. Ensure it accurately reflects the claims against each specific party to avoid jurisdictional challenges later.
Subsequent Treatment
As this is a very recent judgment (February 2025), there is no recorded subsequent treatment in higher or coordinate courts at the time of writing. However, it is expected to be frequently cited in future Art 34(2)(a)(iii) applications involving multi-party arbitration agreements and the scope of non-signatory liability.
Legislation Referenced
- International Arbitration Act 1994 (2020 Rev Ed), s 24(b)
- UNCITRAL Model Law on International Commercial Arbitration, Art 34(2)(a)(ii), Art 34(2)(a)(iii)
- Sale of Goods Act 1979
Cases Cited
- Applied: BZW and another v BZV [2022] 1 SLR 1080
- Applied: CJA v CIZ [2022] 2 SLR 557
- Referred to: [2018] SGHC 147
- Referred to: Recreation Pte Ltd v S Y Technology Inc and another appeal [2008] 2 SLR(R) 491
- Referred to: TMM Division Maritima SA de CV v Pacific Richfield Marine Pte Ltd [2013] 4 SLR 972
- Referred to: BAZ v BBA and others and other matters [2020] 5 SLR 266
- Referred to: Inc and another v Global Gaming Philippines LLC and another [2021] 2 SLR 1279
- Referred to: CBX and another v CBZ and others [2022] 1 SLR 47
- Referred to: CDM and another v CDP [2021] 2 SLR 235
- Referred to: CAJ and another v CAI and another appeal [2022] 1 SLR 505
- Referred to: CKH v CKG and another matter [2022] 2 SLR 1
- Referred to: CIM v CIN [2021] 4 SLR 1176
- Referred to: Equipment Co Ltd v Tornado Consumer Goods Ltd and another matter [2018] 4 SLR 271
- Referred to: Swire Shipping Pte Ltd v Ace Exim Pte Ltd [2024] 5 SLR 706